Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 84 people with Parkinson's disease who received a treatment called rotigotine (delivered as a skin patch). Of the 84 who started, 66 completed the trial and 18 did not finish. The trial was measuring two main things: changes in motor (movement-related) symptoms using a standard Parkinson's rating tool called the UPDRS III, and changes in sleep quality using a Parkinson's-specific sleep questionnaire called the PDSS. Both of these were assessed after 13 weeks of treatment. The reported data shows that, on average, participants' UPDRS III scores — where higher numbers indicate more severe movement problems — changed by minus 5.8 units from the starting point, meaning scores were lower at week 13 than at the beginning. The sleep scale (PDSS) scores also changed by minus 5.8 units on average; on this scale, lower scores indicate fewer sleep-related difficulties. It is worth noting that the two measures used different starting ("baseline") reference points, so they are not directly comparable to each other. The reported data also shows results for two secondary (additional) measures. Scores for nighttime movement difficulties, muscle stiffness, and cramps (measured on a scale of 0–4) changed by an average of minus 1.5 units. The average number of times participants woke during the night to go to the toilet changed by minus 0.4 occasions. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Sleep Disorders Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must have already completed a previous clinical trial called SP889.
Who may not be able to join:
- You are currently experiencing a serious negative health reaction that is believed to be caused by the medication used in the previous trial (SP889).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: UCB Clinical Trial Call Center, +1 877 822 9493 (UCB)
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Change From Baseline in UPDRS III Score at Week 13 (End of Maintenance); Change From Baseline in Parkinson Disease Sleep Scale (PDSS) at Week 13 (End of Maintenance)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.